Precision BioSciences

Precision BioSciences Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Precision BioSciences, Biotechnology company, 302 E. Pettigrew Street, Durham, NC.

05/13/2026

In case you missed the live event, here are a few of our favorite moments from Precision BioSciences’ recent virtual investor event on Duchenne Muscular Dystrophy (DMD)!

Watch the full conversation to hear the Precision team and external experts discuss PBGENE‑DMD and the upcoming Phase 1/2 FUNCTION‑DMD clinical trial.

Click here for the full replay, https://loom.ly/t3XCnQk

05/08/2026

Precision BioSciences announced its first quarter 2026 earnings and provided a business update!

CFO, Alex Kelly, tells you what you need to know.

Read the full press release, https://loom.ly/PeFvD-E

Precisioneer Crystal Gordon’s 44‑kilometer birthday run in support of the Jett Foundation is an incredible example of th...
05/01/2026

Precisioneer Crystal Gordon’s 44‑kilometer birthday run in support of the Jett Foundation is an incredible example of the Duchenne community’s strength and solidarity.

As part of the team at Precision BioSciences, Crystal brings that same commitment to our work on PBGENE‑DMD and the FUNCTION‑DMD Phase 1/2 clinical study for individuals living with Duchenne muscular dystrophy.

Precision is proud to support employees who go above and beyond, both in the lab and in their personal lives, to help move science forward and shine a brighter light on families impacted by Duchenne.

https://loom.ly/MKDV6xI

Precision BioSciences announced a late‑breaking poster presentation for PBGENE‑HBV at the European Association for the S...
04/27/2026

Precision BioSciences announced a late‑breaking poster presentation for PBGENE‑HBV at the European Association for the Study of the Liver (EASL) Congress 2026!

Precision will present new clinical biopsy findings from the ongoing Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV, a first‑in‑class in vivo gene editing treatment candidate designed to eliminate cccDNA and inactivate integrated hepatitis B virus (HBV) DNA in adults with chronic hepatitis B.

Read the full release, https://loom.ly/gNTvRlQ

Nothing beats learning side‑by‑side with families.The Precision BioSciences team recently joined Jett Foundation’s Famil...
04/23/2026

Nothing beats learning side‑by‑side with families.

The Precision BioSciences team recently joined Jett Foundation’s Family Workshop in Salt Lake City, Utah, to listen, learn, and speak with families impacted by Duchenne muscular dystrophy.

We appreciated the opportunity to share more about PBGENE‑DMD and to hear directly from caregivers and clinicians about what matters most as new treatment options move forward.

Learn more about PBGENE-DMD and the Phase 1/2 FUNCTION-DMD study here, https://loom.ly/-wqqxIk

Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial a...
04/16/2026

Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial application approval in two European countries.

“Expanding ELIMINATE-B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE-HBV, the only gene editing therapy uniquely designed to eliminate cccDNA,” said Cindy Atwell, Chief Development and Business Officer of Precision BioSciences. “Given the strong investigator interest in PBGENE-HBV, especially following the late breaker oral presentation at The Liver Conference 2025, these new trial sites will build on our existing global clinical trial footprint as we advance PBGENE-HBV through the ELIMINATE-B trial.”

To learn more, visit https://loom.ly/ore3n7A

Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team present...
04/09/2026

Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team presented new preclinical data on PBGENE‑DMD, the company’s in vivo gene editing candidate designed to restore near full‑length dystrophin and potentially benefit boys with mutations between exons 45–55.

As Debra Miller of CureDuchenne noted, “IND clearance for PBGENE‑DMD is an exciting step forward, and we look forward to collaborating to help connect innovation with the patient families we serve.”

Read the full release, https://loom.ly/-wqqxIk

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE‑DMD, an in vivo gene editing ca...
03/16/2026

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE‑DMD, an in vivo gene editing candidate for the treatment of Duchenne muscular dystrophy (DMD)!

This designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

“Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “We believe this designation, together with our recent IND clearance, supports PBGENE-DMD’s continued momentum towards clinical investigation in boys living with DMD.”

Read the full PR: https://loom.ly/RX7H4kE

Join Precision BioSciences for a virtual investor event on March 17 at 9 am ET!The event features key opinion leaders (K...
03/09/2026

Join Precision BioSciences for a virtual investor event on March 17 at 9 am ET!

The event features key opinion leaders (KOL), Dr. Aravindhan Veerapandiyan, MD, Pediatric Neurologist and Associate Professor of Pediatrics, Arkansas Children’s Hospital, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy, who will join Precision leaders to discuss:

- The unmet need for DMD patients
- Current treatment landscape
- PBGENE-DMD for Duchenne muscular dystrophy (DMD) and
- An overview of the clinical trial design for the FUNCTION-DMD trial

Register here: https://loom.ly/IWJYXbg
Read the full PR, https://loom.ly/RX7H4kE

Address

302 E. Pettigrew Street
Durham, NC
27701

Telephone

+19193145512

Website

Alerts

Be the first to know and let us send you an email when Precision BioSciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Precision BioSciences:

Shortcuts

Share

Category